

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C12N 15/86, 15/45, C07K 14/135, 14/115, A61K 31/70		A1	(11) International Publication Number: WO 99/25858 (43) International Publication Date: 27 May 1999 (27.05.99)
<p>(21) International Application Number: PCT/CA98/01064</p> <p>(22) International Filing Date: 13 November 1998 (13.11.98)</p> <p>(30) Priority Data: 60/065,791 14 November 1997 (14.11.97) US</p> <p>(71) Applicant (<i>for all designated States except US</i>): CONNAUGHT LABORATORIES LIMITED [CA/CA]; 1755 Steeles Avenue West, North York, Ontario M2R 3T4 (CA).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (<i>for US only</i>): PARRINGTON, Mark [CA/CA]; 45 Martin Street, Bradford, Ontario L3Z 1Z4 (CA). LI, Xiaomao [CN/CA]; 106 Glenmanor Way, Thornhill, Ontario L4J 3E5 (CA).</p> <p>(74) Agent: STEWART, Michael, I.; 6th floor, 330 University Avenue, Toronto, Ontario M5G 1R7 (CA).</p>		<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>	

(54) Title: **ALPHAVIRUS VECTORS FOR PARAMYXOVIRUS VACCINES****(57) Abstract**

A DNA vector comprises a first DNA sequence which is complementary to at least part of an alphavirus RNA genome and having the complement of complete alphavirus DNA genome replication regions, and a second DNA sequence encoding a paramyxovirus protein, particularly a respiratory syncytial virus fusion (RSV F) protein or a RSV F protein fragment that generates antibodies that specifically react with RSV F protein, the first and second DNA sequences being under the transcriptional control of a promoter, preferably a cytomegalovirus promoter, which may include Intron A. Such vectors also contain a further nucleotide sequence located between the promoter sequence and the alphavirus sequence to enhance the immunoprotective ability of the RSV F protein when expressed *in vivo*. Such DNA vectors may be used to immunize a host against disease caused by infection with RSV or other paramyxovirus, including a human host, by administration thereto, and may be formulated as immunogenic compositions with pharmaceutically-acceptable carriers for such purposes. Such vectors also may be used to produce antibodies for detection of RSV or other paramyxovirus infection in a sample.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

TITLE OF INVENTIONALPHAVIRUS VECTORS FOR PARAMYXOVIRUS VACCINES

5

FIELD OF INVENTION

The present invention relates to the field of paramyxoviridae vaccines and is particularly concerned with vaccines comprising DNA encoding the fusion (F) 10 protein of respiratory syncytial virus (RSV) in an alphavirus vector.

BACKGROUND OF THE INVENTION

Human respiratory syncytial virus (RSV) has been identified as a major pathogen responsible for severe 15 respiratory tract infections in infants, young children and the institutionalized elderly (refs. 1,2,3,4 - throughout this application, various references are cited in parentheses to describe more fully the state of the art to which this invention pertains. Full 20 bibliographic information for each citation is found at the end of the specification, immediately preceding the claims. The disclosures of these references are hereby incorporated by reference into the present disclosure). Global mortality and morbidity figures indicate that 25 there is an urgent need for an efficacious RSV vaccine (refs. 5,6). In the USA alone, approximately 100,000 children are hospitalized annually with severe cases of pneumonia and bronchiolitis resulting from an RSV infection. Inpatient and ambulatory care for children 30 with RSV infections has been estimated to cost in excess of \$340 million each year in the USA. The World Health Organization (WHO) and the National Institute of Allergy and Infectious Disease (NIAID) vaccine advisory

2

committees have ranked RSV second only to HIV for vaccine development. Both the annual morbidity and mortality figures as well as the staggering health care costs for managing RSV infections have provided the 5 incentive for aggressively pursuing the development of efficacious RSV vaccines. However, such a vaccine is still not available.

Formalin-inactivated (FI-RSV) and live attenuated RSV vaccines have failed to demonstrate efficacy in 10 clinical trials (refs. 7,8,9,10). Moreover, the formalin-inactivated RSV vaccine caused enhanced disease in some children following exposure to wild-type RSV (refs. 7,8,9,10). Elucidation of the mechanism(s) involved in the potentiation of RSV disease is important 15 for the design of safe RSV vaccines, especially for the seronegative population. Recent experimental evidence suggests that an imbalance in cell-mediated responses may contribute to immunopotentiation. Enhanced histopathology observed in mice that were immunized with 20 the FI-RSV and challenged with virus could be abrogated by deletion of CD4+ cells or both interleukin-4 (IL-4) and IL-10.

The RSV fusion (F) glycoprotein is one of the major immunogenic proteins of the virus. This envelope 25 glycoprotein mediates both fusion of the virus to the host cell membrane and cell-to-cell spread of the virus (ref. 1). The F protein is synthesized as a precursor (F₀) molecule which is proteolytically cleaved to form a disulphide-linked dimer composed of the N-terminal F₂, 30 and C-terminal F₁ moieties (ref. 11). The amino acid sequence of the F protein is highly conserved among RSV

3

subgroups A and B and is a cross-protective antigen (refs. 6,12). In the baculovirus expression system, a truncated secreted version of the RSV F protein has been expressed in *Trichoplusia ni* insect cells (ref. 13). The 5 recombinant protein was demonstrated to be protective in the cotton rats (ref. 13).

Studies on the development of live viral vaccines and glycoprotein subunit vaccines against parainfluenza virus infection are being pursued. Clinical trial 10 results with a formalin-inactivated PIV types 1,2,3 vaccine demonstrated that this vaccine was not efficacious (refs. 14, 15, 16). Further development of chemically-inactivated vaccines was discontinued after clinical trials with a formalin-inactivated RSV vaccine 15 demonstrated that not only was the vaccine not effective in preventing RSV infection but many of the vaccinees who later became infected with RSV suffered a more serious disease. Most of parainfluenza vaccine research has focused on candidate PIV-3 vaccines (ref. 17) with 20 significantly less work being reported for PIV-1 and PIV-2. Recent approaches to PIV-3 vaccines have included the use of the closely related bovine parainfluenza virus type 3 and the generation of attenuated viruses by cold-adaptation of the virus 25 (refs. 18, 19, 20, 21).

Another approach to parainfluenza virus type 3 vaccine development is a subunit approach focusing on the surface glycoproteins hemagglutinin-neuraminidase (HN) and the fusion (F) protein (refs. 22, 23, 24). The 30 HN antigen, a typical type II glycoprotein, exhibits both haemagglutination and neuraminidase activities and

is responsible for the attachment of the virus to sialic acid containing host cell receptors. The type I F glycoprotein mediates fusion of the viral envelope with the cell membrane as well as cell to cell spread of the 5 virus. It has recently been demonstrated that both the HN and F glycoproteins are required for membrane fusion. The F glycoprotein is synthesized as an inactive precursor (F) which is proteolytically cleaved into disulfide-linked F2 and F1 moieties. While the HN and F 10 proteins of PIV-1, -2 and -3 are structurally similar, they are antigenically distinct. Neutralizing antibodies against the HN and F proteins of one of PIV type are not cross-protective. Thus, an effective PIV subunit vaccine must contain the HN and F glycoproteins 15 from the three different types of parainfluenza viruses. Antibody to either glycoprotein is neutralizing *in vitro*. A direct correlation has been observed between the level of neutralizing antibody titres and resistance to PIV-3 infections in infants. Native subunit vaccines 20 for parainfluenza virus type 3 have investigated the protectiveness of the two surface glycoproteins. Typically, the glycoproteins are extracted from virus using non-ionic detergents and further purified using lectin affinity or immunoaffinity chromatographic 25 methods. However, neither of these techniques may be entirely suitable for large scale production of vaccines under all circumstances. In small animal protection models (hamsters and cotton rats), immunization with the glycoproteins was demonstrated to prevent infection with 30 live PIV-3 (refs. 25, 26, 27, 28, 29).

The HN and F glycoproteins of PIV-3 have also been produced using recombinant DNA technology. HN and F glycoproteins have been produced in insect cells using the baculovirus expression system and by use of vaccinia 5 virus and adenovirus recombinants (refs. 30, 31, 32, 33, 34). In the baculovirus expression system, both full-length and truncated forms of the PIV-3 glycoproteins as well as a chimeric F-HN fusion protein have been expressed. The recombinant proteins have been 10 demonstrated to be protective in small animal models (see WO91/00104, US Application No. 07/773,949 filed November 29, 1991, assigned to the assignee hereof).

Semliki Forest virus (SFV) is a member of the Alphavirus genus in the Togaviridae family. The mature 15 virus particle contains a single copy of a ssRNA genome with a positive polarity that is 5'-capped and 3'-polyadenylated. It functions as an mRNA and naked RNA can start an infection when introduced into cells. Upon infection/transfection, the 5' two-thirds of the genome 20 is translated into a polyprotein that is processed into the four nonstructural proteins (nsP1 to 4) by self cleavage. Once the ns proteins have been synthesized they are responsible for replicating the plus-strand (42S) genome into full-length minus strands (ref. 14). 25 These minus-strands then serve as templates for the synthesis of new plus-strand (42S) genomes and the 26S subgenomic mRNA (ref. 14). This subgenomic mRNA, which is colinear with the last one-third of the genome, encodes the SFV structural proteins.

30 In 1991 Liljestrom and Garoff (ref. 15) designed a series of expression vectors based on the SFV cDNA

6

replicon. These vectors had the virus structural protein genes deleted to make the way for heterologous inserts, but preserved the nonstructural coding region for production of the nsP1 to 4 replicase complex.

5 Short 5' and 3' sequence elements required for RNA replication were also preserved. A polylinker site was inserted downstream from the 26S promoter followed by translation stop sites in all three frames. An SpeI site was inserted just after the 3' end of the SFV cDNA
10 for linearization of the plasmid for use *in vitro* transcription reactions.

Injection of SFV RNA encoding a heterologous protein have been shown to result in the expression of the foreign protein and the induction of antibody in a number of studies (refs. 16,17). The use of SFV RNA inoculation to express foreign proteins for the purpose of immunization would have several of the advantages associated with plasmid DNA immunization. For example, SFV RNA encoding a viral antigen may be introduced in the presence of antibody to that virus without a loss in potency due to neutralization by antibodies to the virus. Also, because the protein is expressed *in vivo* the protein should have the same conformation as the protein expressed by the virus itself. Therefore, concerns about conformational changes which could occur during protein purification leading to a loss in immunogenicity, protective epitopes and possibly immunopotentiation, could be avoided by plasmid DNA immunization.

30 In copending US Patent Application No. 08/476,397 filed June 7, 1995, assigned to the assignee hereof and

the disclosure of which is incorporated herein by reference (WO96/040945), there is described reference the use of plasmid vectors containing RSV F protein-encoding DNA for DNA immunization against RSV infection.

5 In copending United States Patent Application No. 08/896,500 filed July 18, 1997, assigned to the assignee hereof and the disclosure of which is incorporated herein by reference, there is described the use of plasmid vectors containing RSV G protein-encoding DNA
10 for DNA immunization against RSV infection.

In my copending United States Patent Application No. 08/923,558, filed September 4, 1997, assigned to the assignee hereof and the disclosure of which is incorporated by reference, I describe a DNA vector using
15 an alphavirus vector, including Semliki Forest virus vector, containing a DNA sequence encoding a paramyxovirus protein, specifically RSV-F, for making an RNA transcript for immunization.

In WO95/27044, the disclosure of which is
20 incorporated herein by reference, there is described the use of alphavirus cDNA vectors based on cDNA complementary to the alphavirus RNA sequence. Once transcribed from the cDNA under transcriptional control
25 of a heterologous promoter, the alphavirus RNA is able to self-replicate by means of its own replicase and thereby amplify the copy number of the transcribed recombinant RNA molecules.

Infection with RSV leads to serious disease. It would be useful and desirable to provide improved
30 vectors for *in vivo* administration of immunogenic preparations, including vaccines, for protection against

disease caused by RSV and other paramyxoviruses. In particular, it would be desirable to provide vaccines that are immunogenic and protective in humans, including seronegative infants, that do not cause disease enhancement (immunopotentiation).

SUMMARY OF THE INVENTION

The present invention provides novel immunogenic materials and immunization procedures based on such novel materials for immunizing against disease caused by respiratory syncytial virus. In particular, the present invention is directed towards the provision of DNA vaccines against disease caused by infection with paramyxoviridae.

In accordance with one aspect of the present invention, there is provided a vector, comprising a first DNA sequence which is complementary to at least part of an alphavirus RNA genome and having the complement of complete alphavirus RNA genome replication regions to permit *in vivo* replication; a second DNA sequence encoding a paramyxovirus protein or a protein fragment that generates antibodies that specifically react with the paramyxovirus protein, the second DNA sequence being inserted into a region of the first DNA sequence which is non-essential for replication; the first and second DNA sequences being under transcriptional control of a promoter; and a third DNA sequence located adjacent the second DNA sequence to enhance the immunoprotective ability of the paramyxovirus protein when expressed *in vivo* from the vector in a host.

The paramyxovirus protein may be selected from the group consisting of a parainfluenza virus (PIV) and a respiratory syncytial virus (RSV). The PIV protein may be from PIV-1, PIV-2, PIV-3 or PIV-4, particularly the 5 HN and F glycoproteins of PIV-3. The RSV protein particularly may be the F or G glycoprotein of RSV.

The second DNA sequence may encode a full length RSV F protein, or may encode a RSV F protein lacking the transmembrane anchor and cytoplasmic tail. The 10 lack of the coding region for the transmembrane anchor and cytoplasmic tail results in a secreted form of the RSV F protein. Alternatively, as described in the aforementioned U.S. Patent Application 08/896,500, the second DNA sequence may encode the full-length RSV-G 15 protein or a truncated RSV G protein lacking a transmembrane region, resulting in a secreted form of the protein.

The alphavirus preferably is a Semliki Forest virus and the first DNA sequence is the Semliki Forest viral 20 sequence contained in plasmid pSFVI.

The third nucleotide sequence may comprise a pair of splice sites to prevent aberrant mRNA splicing, *in vivo*, whereby substantially all transcribed mRNA from the vector upon administration encodes the RSV protein. 25 Such third nucleotide sequence is preferably located between the first nucleotide sequence and the promoter sequence. Such third nucleotide sequence may be that of rabbit β -globin intron II, as shown in Figure 8 of copending U.S. Patent Application No. 08/476,397 (WO 30 96/040945).

10

The promoter sequence may be an immediate early cytomegalovirus (CMV) promoter. The human cytomegalovirus Intron A sequence may be provided downstream of the promoter and upstream of the third 5 nucleotide sequence.

A vector encoding the F protein and provided in accordance with one embodiment of the invention may be specifically pMP44, having the identifying characteristics shown in Figure 1D.

10 The vectors provided herein may be used to immunize a host against RSV infection or disease by *in vivo* expression of RSV F protein or RSV G protein, which may lack a transmembrane region, or other paramyxovirus protein, following administration of the vectors. In 15 accordance with a further aspect of the present invention, therefore, there is provided a method of immunizing a host against disease caused by infection with respiratory syncytial virus or other paramyxovirus, which comprises administering to the host an effective 20 amount of a vector provided herein.

The present invention also includes a novel method of using a gene encoding an RSV F or G protein or a fragment of an RSV or G protein capable of generating antibodies which specifically react with RSV F or G 25 protein to protect a host against disease caused by infection with respiratory syncytial virus, which comprises isolating the gene; operatively linking said gene to a DNA sequence which is complementary to at least part of an alphavirus RNA genome and having the 30 complement of complete alphavirus RNA genome replication regions in a region of said DNA sequence which is non-

11

essential for replication to form a vector wherein said gene and DNA sequence are under transcriptional control of a promoter; operatively linking the gene to an immunoprotection enhancing sequence to produce an
5 enhanced immunoprotection by the RSV F or G protein in the host, preferably by introducing the immunoprotection enhancing sequence between the control sequence and the alphavirus sequence; and introducing the vector into the host. A corresponding procedure may be used for other
10 paramyxoviridae.

In addition, the present invention includes a method of producing a vaccine for protection of a host against disease caused by infection with respiratory syncytial virus (RSV), which comprises isolating a first
15 DNA sequence encoding an RSV or G protein, from which the transmembrane anchor and cytoplasmic tail may be absent; operatively linking said first DNA sequence to a second DNA sequence which is complementary to at least part of an alphavirus RNA genome and having the complete
20 alphavirus genome replication regions in a region of said second DNA sequence which is non-essential for replication to form a vector wherein said first and second DNA sequences are under transcriptional control of a promoter; operatively linking the first nucleotide
25 sequence to a third nucleotide sequence to enhance the immunoprotective ability of the RSV F or G protein when expressed in vivo from the vector in a host; and formulating the vector as a vaccine for in vivo administration. A corresponding procedure may be used
30 for other paramyxoviridae.

12

The present invention further includes a vaccine for administration to a host, including a human host, produced by the method as well as immunogenic compositions comprising an immunoeffective amount of the 5 vectors described herein.

BRIEF DESCRIPTION OF DRAWINGS

Figures 1A to 1B show a schematic of a procedure of assembly of vector pMP44;

10 Figures 2A to 2B show a schematic of a procedure of assembly of vector pMP44;

Figures 3A to 3E contain the nucleotide sequence of plasmid pMP44 (SEQ ID NO:1);

15 Figure 4 shows the anti-RSV F titres in sera from mice taken 4 weeks after priming and 2 weeks after boosting;

Figure 5 shows the nucleotide sequence for a synthetic oligonucleotide coding for the hepatitis delta ribozyme (SEQ ID no; 2,3); and

20 Figures 6A to 6C show the nucleotide sequence for the SFV EcoRV-SpeI fragment ligated to the ribozyme of Figure 5 (SEQ ID no: 4).

GENERAL DESCRIPTION OF INVENTION

As described above, the present invention, in general, relates to protection of hosts against disease caused by infection by paramyxovirus by DNA immunization 5 using DNA vectors. In particular, the invention is concerned with protection of hosts against disease caused by infection by respiratory syncytial virus (RSV), although not specifically limited thereto. The description which follows refers specifically to 10 employing DNA sequences encoding RSV F or G protein and fragments thereof which generate antibodies which specifically react with RSV F or G protein.

In this application, the terms "RSV F protein" and "RSV G protein" are used to define a full-length RSV F 15 or G protein, including proteins having variations in their amino acid sequences including those naturally occurring in various strain of RSV and those introduced by PCR amplification of the encoding gene while retaining the immunogenic properties, a secreted form of 20 the RSV F or G protein lacking a transmembrane anchor and cytoplasmic tail, as well as fragments capable of generating antibodies which specifically react with RSV F or G protein and functional analogs. In this application, a first protein is a "functional analog" of 25 a second protein if the first protein is immunologically related to and/or has the same function as the second protein. The functional analog may be, for example, a fragment of the protein or a substitution, addition or deletion mutant thereof.

30 A vector is constructed to contain a first DNA sequence which is complementary to at least part of an

14

alphavirus RNA genome, specifically Semliki Forest virus, and having the complement of complete alphavirus RNA genome replication regions to permit replication *in vivo*. A second DNA sequence encoding the RSV F or G protein is inserted into a region of the first DNA sequence which is non-essential for replication. The first and second DNA sequences are under transcriptional control of a promoter to permit expression of the RSV protein in a host immunized with the vector.

10 The promoter sequence may be the immediately early cytomegalovirus (CMV) promoter. This promoter is described in ref. 36. Any other convenient promoter may be used, including constitutive promoters, such as, Rous Sarcoma Virus LTRs, and inducible promoters, such as
15 metallothioneine promoter, and tissue specific promoters.

The recombinant vector may include a third nucleotide sequence located adjacent the alphavirus sequence to enhance the immunoprotective ability of the RSV F or G protein when expressed *in vivo* in a host.
20 Such enhancement may be provided by increased *in vivo* expression, for example, by increased mRNA stability, enhanced transcription and/or translation. This additional sequence preferably is located between the promoter sequence and the alphavirus sequence.

25 This enhancement sequence may comprise a pair of splice sites to prevent aberrant mRNA splicing during transcription so that substantially all transcribed mRNA is intact alphavirus RNA encoding a gene of interest, for example, an RSV F protein. Specifically, rabbit β -
30 globin Intron II sequence may provide such splice sites, as also described in ref. 37.

15

Additional enhancement may be obtained by, including an additional DNA sequence between the promoter and the enhancer sequence. Such additional DNA sequence may comprise the immediate early 5 cytomegalovirus Intron A sequence.

The vectors provided herein, when administered to an animal, effect *in vivo* RSV F protein expression, as demonstrated by an antibody response in the animal to which it is administered and the conferring of 10 protection. As may be seen from the results detailed in the Examples below, the DNA vectors produced a high anti-F IgG antibody titre and confer protection.

In comparison to the vectors described in the aforementioned U.S. Patent Application nos. 08/476,397 15 and 08/896,500, the vectors described herein provide a protective immune response using a lower dose and less time. In comparison to the vectors described in the aforementioned U.S. Patent Application nos. 08/923,558, 08/896,550 and 08/476,397 using native RSV F, the 20 vectors described herein produce protective immune response in the absence of pretreatment of the animal model with cardiotoxin, a material known to increase the uptake of DNA and enhance the immune response.

The vector provided herein may also comprise a 25 fourth nucleotide sequence encoding a further antigen from RSV, an antigen from at least one other pathogen or at least one immunomodulating agent, such as cytokine. Such vector may contain said fourth nucleotide sequence in a chimeric or a bicistronic structure. Alternatively, 30 vectors containing the fourth nucleotide sequence may be

16

separately constructed and coadministered to a host, with the DNA vector provided herein.

In addition, there may be provided at the 3'-end of the Simliki Forest virus segment, a hepatitis delta 5 virus ribosyme sequence to ensure proper *in vivo* cleavage at the 3'-end of the Simliki Forest virus sequence. Any other convenient sequence may be employed to achieve this effect.

It is clearly apparent to one skilled in the art, 10 that the various embodiments of the present invention have many applications in the fields of vaccination, diagnosis and treatment of RSV infections. A further non-limiting discussion of such uses is further presented below.

15 1. Vaccine Preparation and Use

Immunogenic compositions, suitable to be used as vaccines, may be prepared from the RSV F or RSV G genes and other paramyxovirus genes and vectors as disclosed herein. The vaccine elicits an immune response in a 20 subject which includes the production of anti-F or anti-G antibodies. Immunogenic compositions, including vaccines, containing the DNA vector may be prepared as injectables, in physiologically-acceptable liquid solutions or emulsions for polynucleotide 25 administration. The nucleic acid may be associated with liposomes, such as lecithin liposomes or other liposomes known in the art, as a nucleic acid liposome (for example, as described in WO 93/24640, ref. 38) or the DNA vector may be associated with an adjuvant, as 30 described in more detail below. Liposomes comprising cationic lipids interact spontaneously and rapidly with

17

polyanions such as DNA and RNA, resulting in liposome/nucleic acid complexes that capture up to 100% of the polynucleotide. In addition, the polycationic complexes fuse with cell membranes, resulting in an 5 intracellular delivery of polynucleotide that bypasses the degradative enzymes of the lysosomal compartment. Published PCT application WO 94/27435 describes compositions for genetic immunization comprising cationic lipids and polynucleotides. Agents which 10 assist in the cellular uptake of nucleic acid, such as calcium ions, viral proteins and other transfection facilitating agents, may advantageously be used.

Polynucleotide immunogenic preparations may also be formulated as microcapsules, including biodegradable 15 time-release particles. Thus, U.S. Patent 5,151,264 describes a particulate carrier of a phospholipid/glycolipid/polysaccharide nature that has been termed Bio Vecteurs Supra Moléculaires (BVSM). The particulate carriers are intended to transport a variety 20 of molecules having biological activity in one of the layers thereof.

U.S. Patent 5,075,109 describes encapsulation of the antigens trinitrophenylated keyhole limpet hemocyanin and staphylococcal enterotoxin B in 50:50 25 poly (DL-lactide-co-glycolide). Other polymers for encapsulation are suggested, such as poly(glycolide), poly(DL-lactide-co-glycolide), copolyoxalates, polycaprolactone, poly(lactide-co-caprolactone), poly(esteramides), polyorthoesters and poly(8- 30 hydroxybutyric acid), and polyanhydrides.

Published PCT application WO 91/06282 describes a delivery vehicle comprising a plurality of bioadhesive microspheres and antigens. The microspheres being of starch, gelatin, dextran, collagen or albumin. This 5 delivery vehicle is particularly intended for the uptake of vaccine across the nasal mucosa. The delivery vehicle may additionally contain an absorption enhancer.

The RSV F or G genes and vectors may be mixed with pharmaceutically acceptable excipients which are 10 compatible therewith. Such excipients may include, water, saline, dextrose, glycerol, ethanol, and combinations thereof. The immunogenic compositions and vaccines may further contain auxiliary substances, such as wetting or emulsifying agents, pH buffering agents, 15 or adjuvants to enhance the effectiveness thereof. Immunogenic compositions and vaccines may be administered parenterally, by injection subcutaneously, intravenously, intradermally or intramuscularly, possibly following pretreatment of the injection site 20 with a local anaesthetic. Alternatively, the immunogenic compositions formed according to the present invention, may be formulated and delivered in a manner to evoke an immune response at mucosal surfaces. Thus, the immunogenic composition may be administered to 25 mucosal surfaces by, for example, the nasal or oral (intragastric) routes. Alternatively, other modes of administration including suppositories and oral formulations may be desirable. For suppositories, binders and carriers may include, for example, 30 polyalkalene glycols or triglycerides. Oral formulations may include normally employed incipients,

19

such as, for example, pharmaceutical grades of saccharine, cellulose and magnesium carbonate.

The immunogenic preparations and vaccines are administered in a manner compatible with the dosage formulation, and in such amount as will be therapeutically effective, protective and immunogenic. The quantity to be administered depends on the subject to be treated, including, for example, the capacity of the individual's immune system to synthesize the RSV F protein and antibodies thereto, and if needed, to produce a cell-mediated immune response. Precise amounts of active ingredient required to be administered depend on the judgment of the practitioner. However, suitable dosage ranges are readily determinable by one skilled in the art and may be of the order of about 1 µg to about 1 mg of the RSV F or G genes and vectors. Suitable regimes for initial administration and booster doses are also variable, but may include an initial administration followed by subsequent administrations. The dosage may also depend on the route of administration and will vary according to the size of the host. A vaccine which protects against only one pathogen is a monovalent vaccine. Vaccines which contain antigenic material of several pathogens are combined vaccines and also belong to the present invention. Such combined vaccines contain, for example, material from various pathogens or from various strains of the same pathogen, or from combinations of various pathogens.

In particular embodiments of the present invention, the vector comprising a first nucleotide sequence

20

encoding an F or G protein of RSV may be delivered in conjunction with a targeting molecule to target the vector to selected cells including cells of the immune system.

5 The DNA vectors may be delivered to the host by a variety of procedures, for example, Tang et al. (ref. 39) disclosed that introduction of gold microprojectiles coated with DNA encoding bovine growth hormone (BGH) into the skin of mice resulted in production of anti-BGH
10 antibodies in the mice, while Furth et al. (ref. 40) showed that a jet injector could be used to transfect skin, muscle, fat and mammary tissues of living animals.

2. Immunoassays

The RSV F or G genes and vectors of the present invention are useful as immunogens for the generation of anti-F or anti-G antibodies for use in immunoassays, including enzyme-linked immunosorbent assays (ELISA), RIAs and other non-enzyme linked antibody binding assays or procedures known in the art. In ELISA assays, the
15 vector first is administered to a host to generate antibodies specific to the RSV F or G protein or other paramyxovirus protein. These RSV F- or G-specific antibodies are immobilized onto a selected surface, for example, a surface capable of binding the antibodies,
20 such as the wells of a polystyrene microtiter plate. After washing to remove incompletely adsorbed antibodies, a nonspecific protein such as a solution of bovine serum albumin (BSA) that is known to be antigenically neutral with regard to the test sample may
25 be bound to the selected surface. This allows for blocking of nonspecific adsorption sites on the
30

21

immobilizing surface and thus reduces the background caused by nonspecific bindings of antisera onto the surface.

The immobilizing surface is then contacted with a sample, such as clinical or biological materials, to be tested in a manner conducive to immune complex (antigen/antibody) formation. This procedure may include diluting the sample with diluents, such as solutions of BSA, bovine gamma globulin (BGG) and/or phosphate buffered saline (PBS)/Tween. The sample is then allowed to incubate for from about 2 to 4 hours, at temperatures such as of the order of about 20° to 37°C. Following incubation, the sample-contacted surface is washed to remove non-immunocomplexed material. The washing procedure may include washing with a solution, such as PBS/Tween or a borate buffer. Following formation of specific immunocomplexes between the test sample and the bound RSV F specific antibodies, and subsequent washing, the occurrence, and even amount, of immunocomplex formation may be determined.

Biological Deposits

Certain vectors that contain the gene encoding RSV F protein and referred to herein have been deposited with the American Type Culture Collection (ATCC) located at 10801 University Boulevard, Manassas, VA 20110-2209, U.S.A., pursuant to the Budapest Treaty and prior to the filing of this application.

Samples of the deposited plasmids will become available to the public upon grant of a patent based upon this United States patent application and all restrictions on access to the deposits will be removed

22

at that time. Non-viable deposits will be replaced. The invention described and claimed herein is not to be limited in scope by plasmids deposited, since the deposited embodiment is intended only as an illustration 5 of the invention. Any equivalent or similar plasmids that encode similar or equivalent antigens as described in this application are within the scope of this invention.

Deposit Summary

	<u>Plasmid</u>	<u>ATCC Designation</u>	<u>Date Deposited</u>
10	pMP37	97905	Feb. 27, 1997
	pMP42		

EXAMPLES

The above disclosure generally describes the 15 present invention. A more complete understanding can be obtained by reference to the following specific Examples. These Examples are described solely for purposes of illustration and are not intended to limit the scope of the invention. Changes in form and 20 substitution of equivalents are contemplated as circumstances may suggest or render expedient. Although specific terms have been employed herein, such terms are intended in a descriptive sense and not for purposes of limitations.

25 Methods of molecular genetics, protein biochemistry and immunology used but not explicitly described in this disclosure and these Examples are amply reported in the scientific literature and are well within the ability of those skilled in the art.

EXAMPLE 1

This Example describes a scheme for construction of a Semliki Forest Virus (SFV) DNA expression vector containing a truncated RSV F gene as outlined in 5 Figures 1A to 1B.

Plasmid VR1012 was restricted with PstI and then made blunt-ended with T4 DNA polymerase. The β -globin Intron II was excised out of vector pSG5 (Stratagene) and ligated into plasmid VR1012 to generate plasmid 10 pIIIE. Plasmid pIIIE was then restricted with SalI and EcoRV and ligated to a PCR fragment having the nucleotide sequence:

TCGACATGGCGGATGTGTGACATACACGACGCCAAAGATTTGTTCCAGCT
CCTGCCACCTCCGCTACGCGAGAGATTAACCACCCACGATGGCCGCCAAAGT
15 GCATGTTGATATTGAGGCTGACAGCCCATTCAAGTCTTGAGAAGGCA
TTTCCCGTCGTTCGAGGTGGAGTCATTGCAGGTACACCAAATGACCATGCAA
ATGCCAGAGCATTTCGCACCTGGCTACCAAATTGATCGAGCAGGAGACTGA
CAAAGACACACTCATCTTGGAT (SEQ ID no: 7) generated from 20 pSFV1 with primers SAL-SFV having the nucleotide sequence 5'-TCCACCTCCAAGATATCCAAGATGAGTGTG (SEQ ID no: 5) and ECO-SFV having the nucleotide sequence 5'-TCCACCTCCAAGATATCCAAGATGAGTGTG (SEQ ID no: 6). The resulting plasmid pMP38 was then restricted with EcoRV and BamHI and then dephosphorylated. Plasmid pSFV1 25 link (see copending application no. _____ (b/o 1038-766)) was then restricted with SpeI and ligated to the hepatitis delta ribozyme (Fig. 5, SEQ ID nos: 2 and 3). The ligation reaction was then restricted with EcoRV to release most of the SFV-RSVF plus ribozyme 30 fragment. This fragment was then ligated to EcoRV/BamH1 restricted pMP38 to produce pMP41.

Example 2

This Example describes an alternative scheme for constructing plasmid pMp44 as outlined in Figure 2.

Plasmid VR1012 was restricted with PstI and then 5 made blunt-ended with T4 DNA polymerase. The β-globin Intron II was excised out of vector pSG5 (Stratagene) and ligated into plasmid VR1012 to generate plasmid pIIIE. Plasmid pIIIE was then restricted with SalI and EcoRV and ligated to a PCR fragment having the 10 nucleotide sequence:

TCGACATGGCGGATGTGTGACATACACGACGCCAAAGATTGTTCCAGCT
CCTGCCACCTCCGCTACGCGAGAGATTAACCACCCACGATGGCCGCCAAAGT
GCATGTTGATATTGAGGCTGACAGCCCATTCATCAAAGTCTTGCAGAAGGCA
TTTCCCGTCTCGAGGTGGAGTCATTGCGAGGTACACCAAATGACCATGCAA
15 ATGCCAGAGCATTTCGCACCTGGCTACCAAATTGATCGAGCAGGAGACTGA
CAAAGACACACTCATCTTGGAT (SEQ ID no: 7) generated from pSFV1 with primers SAL-SFV having the nucleotide sequence 5'-TCCACCTCCAAGATATCCAAGATGAGTGTG (SEQ ID no: 5) and ECO-SFV having the nucleotide sequence 5'-
20 TCCACCTCCAAGATATCCAAGATGAGTGTG (SEQ ID no: 6). The resulting plasmid pMP38 was then restricted with EcoRV and BamHI and then dephosphorylated. Plasmid pSFV1 link (see copending application no. _____ (b/o 1038-766)) was then restricted with SpeI and ligated to
25 the hepatitis delta ribozyme (Fig. 5, SEQ ID nos: 2 and 3).

The ligation reaction product was then restricted with EcoRV to release the SFV replicon plus the ribozyme having the nucleotide sequence as outlines in 30 Figures 6A to 6C. This fragment was then ligated to the EcoRV/BamHI restricted pMP38 to produce pMP42. The

25

RSV F gene fragment was released from pMP37 by restriction with BamHI, and this fragment was ligated into the BamHI site of pMP42 to produce pMP44. The nucleotide sequence of pMP44 is shown in Figures 3A to
5 3E.

EXAMPLE 3

This Example describes the immunization of mice with pMP44 and the immunogenicity results obtained.

BALB/C mice were immunized with plasmid pMP44 by
10 the intramuscular (i.m.) route. The anterior tibialts muscles of six BALB/C mice were bilaterally injected with 2 x 100 µg of plasmid pMP44. This amount is equivalent to approximately 94µg of a conventional vector, based on copy number. These mice were boosted
15 in an identical manner 4 weeks later. The control group was immunized with 2 x 25 µg of SFV-RSV F RNA as described in my aforementioned United States Application No. 08/923,558, except that the muscles were not pre-treated with cardiotoxin. The
20 immunization protocol is set forth in the following

Table I:

Table 1 Immunization protocol

Group	Prime	Route of Inoculation	Boost	Route of Inoculation
25	1 SFV-RSVF RNA ¹	Intramuscular	SFV-RSVF RNA ¹	Intramuscular
	2 pMP44 DNA ²	Intramuscular	pMP44DNA ²	Intramuscular

Mice were inoculated with:

1. 25µg of RNA was injected into each hind leg muscle in 50 µL of PBS
- 30 2. 100 µg of DNA was injected into each hind leg muscle in 50µL of PBS

Sera was obtained from the mice at 4 and 6 weeks. Anti-RSV F antibody titres (IgG) in these sera were determined by enzyme-linked immunosorbent assay (ELISA), as described in Example 3.

5 The anti-RSV F IgG antibody response in the sera of the BALB/C mice are summarized in Figure 4. The mice immunized with the DNA construct, pMP44, had higher anti-F titres than the mice immunized with the SFV-RSV F RNA.

10 Two weeks after the second immunization, mice were challenged intranasally with 10^6 plaque forming units (pfu) of the A1 strain of RSV (BG-4A). Animals were sacrificed 4 days later. Lungs were aseptically removed, weighed, and homogenized in 2 mL of complete 15 culture medium. The virus titre in lung homogenates was determined in duplicate using vero cells, as previously described (ref. 41).

As seen in Table 2 below, immunization of mice with pMP44 DNA protected mice (5/6) against live RSV 20 challenge, in contrast to the lack of protection when immunization with SFV-RSV F RNA was effected. This result contrasts with the complete protection which is obtained using SFV-RSV F RNA as described in U.S. Patent Application Nos. 08/923,558, 08/476,397 and 25 08/896,500 where the results show protection after pretreatment with cardiotoxin.

Table 2

Group	Immunogen		Mean Virus Lung Titre (log ₁₀ /g±s.d) % Protection	
	Prime	Boost		
30	1 SFV-RSVF RNA	SFV-RSVF RNA	4.26	0
	2 pMP44 DNA	pMP44DNA	2.12*	83

* Limit of detection = 1.8

EXAMPLE 4

This Example describes the determination of anti-
5 RSV F antibody titres.

Nunc-MaxiSorp plate wells were coated overnight at room temperature with 2.5 ng of immunoaffinity-purified RSV F protein diluted in 0.05M carbonate-bicarbonate buffer, pH 9.6. Wells were blocked for non-specific binding by adding 0.1% BSA in PBS for 30 min. at room 10 temperature, followed by two washes in a washing buffer of 0.1% BSA in PBS + 0.1% Tween 20. Serial two or four-fold dilutions of mouse serum was added to the wells. After a one hour incubation at room 15 temperature, plates were washed five times with washing buffer, and horseradish peroxidase (HRP) labeled conjugate was added at the appropriate optimal dilution in washing buffer. The total IgG assay used F(ab'), goat antimouse IgG (H+L specific)- HRP from Jackson 20 Immuno Research Laboratory Inc. (Baltimore, MD, USA). Sheep anti-mouse IgG1-HRP from Serotec (Toronto, Ontario, Canada) was used in the IgG1 assay and goat anti-mouse IgG2a from Caltag Laboratories (San Francisco, CA, USA) was used in the IgG2a assay. 25 Following one hour incubation at room temperature, the plates were washed five times with washing buffer, and hydrogen peroxide (substrate) in the presence of tetramethylbenzidine was added. The reaction was stopped by adding 2 M sulfuric acid. The colour was 30 read in a Multiscan Titertek plate reader at an optical density (OD) of 450 nm. The titre was taken as the reciprocal of the last dilution at which the OD was

28

approximately double. This OD must be greater than the negative control of the assay at the starting dilution. The pre-immune serum of each animal was used as the negative control.

5 SUMMARY OF THE DISCLOSURE

In summary of this disclosure, the present invention provides certain novel alphavirus derived DNA vectors containing genes encoding RSV F or RSV G proteins, or other paramyxovirus proteins, methods of 10 immunization using such vectors and methods of diagnosis using such vectors. Modifications are possible within the scope of this invention.

REFERENCES

1. McIntosh K. and Chanock R.M. in Fields B.N. and Knipe D.M. (eds). *Virology*. Raven Press, New York, 1990, pp.1045-1072.
- 5 2. Murphy B.R., Hall S.L., Kulkarni A.B., Crowe J.E., Collins P.L., Connors M., Karron R.A. and Chanock R.M., *Virus Res* 32, 13-36, 1994.
- 10 3. Osterweil D. and Norman D., *Am Geriat Soc* 36, 659-662, 1990.
- 15 4. Agius G., Dindinand G., Biggar R.J., Peyre R., Vaillant V., Ranger S., Poupet J.Y., Cisse M.F. and Casters M., *J Med Virol* 30, 117-127, 1990.
- 20 5. Katz S.L. in *New vaccine development establishing priorities Vol 1*. National Academic Press, Washington, 1985, pp. 3974 09.
6. Wertz G.W. and Sullender W.M., *Biotechnology* 20, 151-176, 1992 .
- 25 7. Fulginiti V.A., Eller J.J., Sieber O.F., Joyner J.W., Minamitani M. and Meiklejohn G., *Am J Epidemiol* 89, 449-463, 1969.
- 30 8. Chin J., Magoffin R.L., Shearer I.A., Schieble J.H. and Lennette E.H., *Am J Epidemiol* 89, 449-463, 1969.
- 35 9. Belshe R.B., Van Voris L.P. and Mufson M.A., *J Infect Dis* 145, 311-319, 1982.
10. Kim R.M., Arroboio J.O., Pyles G., Brandt C.D., Camargo E., Chanock R.M. and Parrott R.H., *Pediatrics* 48, 745-755, 1971.
- 40 11. Gruber C. and Levine S., *J Gen Virol* 64, 825-832, 1983.
12. Olmstead R.A., Elango N. and Prince G.A., *Proc Natl Acad Sci USA* 88, 7462-7466, 1991.

30

13. Parrington M., Cockle S., Wyde P., Du R.-P., Snell E., Yan W.-Y., Wang Q., Gisonni L., Sanhueza S., Ewasyshyn M. and Klein M., Virus Genes 14, 65-74, 1997
- 5 14. Fulginiti, V.A., Eller, J.J., Sieber, O.F., Joyner, J.W., Minamitani, M. and Meiklejohn, G. (1969) Am. J. Epidemiol. 89 (4), 435-448.
- 10 15. Chin, J., Magoffin, R.L., Shearer, L.A., Schieble, J.H. and Lennette, E.H. (1969) Am. J. Epidemiol. 89 (4), 449-463.
- 15 16. Jensen, K.E., Peeler, B.E. and Dulworth, W.G. (1962) J. Immunol. 89, 216-226.
- 20 17. Murphy, B.R., Prince, G.A., Collins, P.L., Van Wyke -Coelingh, K., Olmsted, R.A., Spriggs, M.K., Parrott, R.H., Kim, H.-Y., Brandt, C.D. and Chanock, R.M. (1988) Vir. Res. 11, 1-15.
- 25 18. Hall, S.L., Sarris, C.M., Tierney, E.L., London, W.T., and Murphy, B.R. (1993) J. Infect. Dis. 167, 958-962.
- 30 19. Belshe, R.B., Karron, R.A., Newman, F.K., Anderson, E.L., Nugent, S.L., Steinhoff, M., Clements, M.L., Wilson, M.H., Hall, S.L., Tierney, E.L. and Murphy, B.R. (1992) J. Clin. Microbiol. 30 (8), 2064-2070.
20. Hall, S.L., Stokes, A., Tierney, E.L., London, W.T., Belshe, R.B., Newman, F.C. and Murphy, B.R. (1992) Vir. Res. 22, 173-184.
- 35 21. Van Wyke Coelingh, K.L., Winter, C.C., Tierney, E.L., London, W.T. and Murphy, B.R. (1988) J. Infect. Dis. 157 (4), 655-662.
- 40 22. Ray, R., Novak, M., Duncan, J.D., Matsuoka, Y. and Compans, R.W. (1993) J. Infect. Dis. 167, 752-755.
23. Ray, R., Brown, V.E. and Compans, R.W. (1985) J. Infect. Dis. 152 (6), 1219-1230.
- 45 24. Ray, R. and Compans, R.W. (1987) J. Gen. Virol. 68, 409-418.

25. Ray, R., Glaze, B.J., Moldoveanu, Z. and Compans, R.W. (1988) J. Infect. Dis. 157 (4), 648-654.
- 5 26. Ray, R., Matsuoka, Y., Burnett, T.L., Glaze, B.J. and Compans, R.W. (1990) J. Infect. Dis. 162, 746-749.
- 10 27. Ray, R., Glaze, B.J. and Compans, R.W. (1988) J. Virol. 62 (3), 783-787.
- 15 28. Ewasyshyn, M., Caplan, B., Bonneau A.-M., Scollard, N., Graham, S., Usman, S. and Klein, M. (1992) Vaccine 10 (6), 412-420.
- 20 29. Ambrose, M.W., Wyde, P.R., Ewasyshyn, M., Bonneau, A.-M., Caplan, B., Meyer, H.L. and Klein, M. (1991) Vaccine 9, 505-511.
- 25 30. Kasel, J.A., Frank, A.L., Keitel, W.H., Taber, L.H., Glezen W.P. J. Virol. 1984; 52:828-32.
31. Lehman, D.J., Roof, L.L., Brideau, R.J., Aeed, P.A., Thomsen, D.R., Elhammer, A.P., Wathen, M.W. and Homa, F.L. (1993) J. Gen. Virol. 74, 459-469.
- 25 32. Brideau, R.J., Oien, N.L., Lehman, D.J., Homa, F.L. and Wathen, M.W. (1993) J. Gen. Virol. 74, 471-477.
- 30 33. Ebata, S.N., Prevec, L., Graham, F.L. and Dimock, K. (1992) Vir. Res. 24, 21-33.
34. Hall, S.L., Murphy, B.R. and Van Wyke Coelingh, K.L. (1991) Vaccine 9, 659-667.
- 35 35. Strauss E.G. and Strauss J.H., in Schlesinger S.S. and Schlesinger M.i. (eds). The Togaviridae and Flaviviridae. Plenum Press, New York, 1986, pp.35-90.
- 40 36. Chapman, B.S.; Thayer, R.M.; Vincent, K.A. and Haigwood, N.L., Nucl. Acids. Res. 1991, 19: 3979-3986.
- 45 37. Breathnack, R. and Harris, B.A., Nucl. Acids Res. 1983, 11: 7119-7136

38. Nabel, G.J. 1993, Proc. Natl. Acad. Sci. USA 90: 11307-11311.
- 5 39. Tang et al., Nature 1992, 356: 152-154
40. Furth et al. Analytical Biochemistry, 1992, 205: 365-368
- 10 41. Prince, G.A. et al, Am. J. Pathol. 93, 771 to 790, 1978.

33
CLAIMS

What we claim is:

1. A vector, comprising:

5 a first DNA sequence which is complementary to at least part of an alphavirus RNA genome and having the complement of complete alphavirus RNA genome replication regions to permit *in vivo* replication; and
 a second DNA sequence encoding a paramyxovirus
10 protein or a protein fragment that generates antibodies that specifically react with the paramyxovirus protein, the second DNA sequence being inserted into a region of the first DNA sequence which is non-essential for replication, the first and second DNA sequences being
15 under transcriptional control of a promoter.

2. The vector of claim 1 wherein the paramyxovirus protein is selected from the group consisting of a parainfluenza virus (PIV) and a respiratory syncytial virus (RSV).

20 3. The vector of claim 2 wherein the PIV protein is selected from the group consisting of PIV-1, PIV-2, PIV-3 and PIV-4

25

4. The vector of claim 3 wherein said PIV protein is selected from the group consisting of the HN and F glycoproteins of PIV-3.

34

5. The vector of claim 4 wherein the RSV protein is selected from the group consisting of the F or G glycoprotein of RSV.
- 5 6. The vector of claim 1 wherein the second DNA sequence encodes a full length RSV F or RSV G proteins.
7. The vector of claim 1, wherein the second nucleotide sequence encodes a truncated RSV F or RSV G
10 protein lacking the transmembrane anchor and cytoplasmic tail.
8. The vector of claim 1 wherein the alphavirus is a Semliki Forest virus.
- 15 9. The vector of claim 1 wherein the first DNA sequence is the Semliki Forest viral sequence contained in plasmid pSFVI.
- 20 10. The vector of claim 1 wherein the promoter sequence is an immediate early cytomegalovirus (CMV) promoter.
11. The vector of claim 1 further comprising a third DNA sequence located adjacent the second DNA sequence
25 to enhance the immunoprotective ability of the paramyxovirus protein when expressed *in vivo* from the vector in a host.
12. The vector of claim 11 wherein the third nucleotide sequence comprises a pair of splice sites to prevent aberrant mRNA splicing, *in vivo* whereby substantially
30

35

all transcribed mRNA from the vector region administration encodes the RSV protein.

13. The vector of claim 12 wherein the third nucleotide
5 sequence is located between the first nucleotide
sequence and the promoter sequence.

14. The vector of claim 13 wherein said third
nucleotide sequence is that of rabbit β -globin intron
10 II.

15. The vector of claim 10 wherein said promoter
sequence is an immediate early cytomegalovirus (CMV)
promoter and the human cytomegalovirus Intron A
15 sequence is provided downstream of the promoter and
upstream of the third nucleotide sequence.

16. The vector of claim 15 further comprising a fourth
nucleotide sequence at the 3'-end of the first
20 nucleotide sequence to ensure proper *in vivo* cleavage
at the 3'-end of the first nucleotide sequence.

17. The vector of claim 16 wherein said fourth
nucleotide sequence is a hepatitis delta virus ribozyme
25 sequence.

18. The vector of claim 1 which has the identifying
characteristics of plasmid pMP44 shown in Figure 2D.

30 19. The vector of claim 1 which has SEQ ID No: 1.

36

20. A method of immunizing a host against disease caused by infection with paramyxovirus, which comprises administering to the host an effective amount of a vector as claimed in claim 1.

5

21. The method of claim 21 wherein said vector has the identifying characteristics of plasmid pMP44 shown in Figure 2D.

10 22. The method of claim 21 wherein said vector has SEQ ID no: 1.

15 23. A method of using a gene encoding an RSV F or G protein or a fragment of an RSV or G protein capable of generating antibodies which specifically react with RSV F or G protein to protect a host against disease caused by infection with respiratory syncytial virus, which comprises:

isолating said gene;

20 operatively linking said gene to a DNA sequence which is complementary to at least part of an alphavirus RNA genome and having the complement of complete alphavirus RNA genome replication regions in a region of said DNA sequence which is non-essential for replication 25 to form a vector wherein said gene and DNA sequence are under transcriptional control of a promoter; and introducing the vector into the host.

24. The method of claim 23 wherein said gene encoding 30 an RSV F protein encodes an RSV F protein lacking the transmembrane region.

25. The method of claim 24 wherein said promoter comprises the immediate early cytomegalovirus promoter.

5 26. The method of claim 25 including the step of:
operatively linking said gene to an immunoprotective enhancing sequence to produce an enhanced immunoprotection to said RSV F protein in said host.

10

27. The method of claim 26 wherein said immunoprotective enhancing sequence is introduced into said vector between said control sequence and said gene.

15 28. The method of claim 27 wherein said immunoprotection enhancing sequence comprises a pair of splice sites to prevent aberrant mRNA splicing whereby substantially intact transcribed mRNA encodes an RSV F protein.

20

29. The method of claim 28 wherein said immunoprotection enhancing sequence is that of rabbit β -globin intron II.

25 30. The method of claim 23 wherein said vector is plasmid pMP44.

31. The vector of claim 23 wherein said vector has SEQ ID no: 1.

30

38

32. A method of producing a vaccine for protection of a host against disease caused by infection with respiratory syncytial virus (RSV), which comprises:

5 isolating a first DNA sequence encoding an RSV or G protein, from which the transmembrane anchor and cytoplasmic tail may be absent;

10 operatively linking said first DNA sequence to a second DNA sequence which is complementary to at least part of an alphavirus RNA genome and having the complete alphavirus genome replication regions in a region of said second DNA sequence which is non-essential for replication to form a vector wherein said first and second DNA sequences are under transcriptional control of a promoter; and

15 formulating the vector as a vaccine for *in vivo* administration.

33. The composition of claim 32 wherein said vector has the identifying characteristics of pMP44 shown in Figure
20 2D.

34. The method of claim 32 wherein said vector has SEQ ID no: 1.

25 35. A vaccine for administration to a host, including a human host, produced by the method of claim 32.

36. An immunogenic composition comprising an immunoeffective amount of a vector of claim 1.

39

37. The composition of claim 36 wherein said vector has
the identifying characteristic of pMP44 in Figure 2D.
38. The composition of claim 36 wherein said vector has
5 SEQ ID no: 1.

1/16

Figure 4 Construction of pMP44




FIG. 4-4 1A





Fig 1B

3/16



+ Bam H-I fragment
from pMP42



L. M. 12



FIG 1C




FIG 10

5/16


Figure 1 Construction of pMP44

FIG. 2A




Figure 3 Nucleotide sequence of plasmid pMP44

tcgcgcgtt cggatgac ggtaaaaacc tctgacatc gcagccccg gagacggta 60
 cagttgtct gtaaggat gccggagca gacaagccc tcagggcg cgtaggggt 120
 ttggcggtg tcgggctgg cttaactatg cggcatcaga gcagattgt ctgagagtgc 180
 accatatgcg gtgtaaaata ccgcacagat gcgtaaaggag aaaataccgc atcagattgg 240
 ctattggcca ttgcatacgt tggatccata tcataatatg tacattata ttggctcatg 300
 tccaacatta cccgcattgtt gacattgtt attgactatgt tattaaatgtt aatcaattac 360
 ggggtcattt gttcatagca catatatggt gtccggcggtt acataactt ccgtaaatgg 420
 cccgcctgac tgaccggcca acgacccccc ccattgtacgc tcaataatgt cgtatgttc 480
 catagtaaccc ccaataggga ctttcattt acgtcaatggt gtggagtat tacgtaaaac 540
 tgcccaacttgc gcagttacatc aagtgtatca tatgccaatgc acgcccccta ttgacgtcaa 600
 tgacggtaaa tggccgcctt ggattatgc ccagttacatg accttattgg actttcttac 660
 ttggcgtatc atctacgtat tagtcattgc tattaccatg gtatgtcggtt ttggcgatgt 720
 catcaatggg cgtggatagc ggtttgactc acggggattt ccaagtctcc acccattgt 780
 cgtcaatggg agtttgtttt ggacccaaaa tcaacgggac tttccaaatgtcgtaaaca 840
 ctccgcggccca ttgacgcataa tggcggttag gggtgtacgg tggaggtct atataagcag 900
 agtcgttta gtaaccgtc agatcgccgt gagaacgcattt ccacgttgc ttgacccctca 960
 tagaaggcccg cgggacccgt ccagectccg cggccgggaa cgtgtccatgg aacgcggat 1020
 tccccgtgcc aagagtacg taatgtaccgc tataagactc tataaggcaca ccccttggc 1080
 tcttatgtatcgtatgttggatggtggccctatac acccccgctt ctttatgtca 1140
 taggtgtatgg tatagttttag cctatagggtt tgggttattt accattattt accactcccc 1200
 tattgggtac gatacttcc attactaatc cataacatgg ctctttggca caactatctc 1260
 tattggctat atgccaatac tctgtccctt acagactgac acggactctg tatttttaca 1320
 ggatgggggtc ccatttata ttacaaaattt cacatataca acaacgcgtt ccccggtgcc 1380
 cgcagttttt attaaacata gctggggatc tccacgcgaa tctcgggtac gtgttccgga 1440
 catgggtctt ttcgggttag cggccggatc tccacatccg acggccgttcc ccatgeetcc 1500
 agcggctcat ggtcgctccg cagetccttg ctccatacag tggaggcccg acttaggcac 1560
 agcacaatgc ccaccaccac cagtgccgc cagaaggccg tggcggttagg gtatgtgtct 1620
 gaaaatgac gtggagattt ggctcgacag gctgacgcag atggaaagact taaggcagcg 1680
 gcagaagaag atgcaggcag ctgatgtttt gtattctgtat aagagtcaaga ggtaaactccc 1740
 gttgcgggtc tggtaacgggtt ggagggcagt gtatgtcgat cagttactgt tgcgtccgc 1800
 cggccacca gacataatag ctgacagact aacagactgt tcctttccat gggcttttc 1860
 cgatccgtt aacttcagggt tgagtttggg gacccttgcgtt ttttcgttat 1920
 tgtaaaaattt atgttatatg gaggggccaa agttttccgg tggatgtttt gaatggaaag 1980
 atgtcccttgc ttttccatgc gaccctcatg ataattttgtt ttctactctg 2040
 ttgacaacca ttgtcccttc ttattttttgc ttcattttttgc ttaactttttt cgttaaactt 2100
 tagcttgcattt ttgtaacggaa ttttttttttt cacttttttttgc ttttgcatttgc attgttaagta 2160
 ctttctctaa tcactttttt ttcaaggcaaa tcagggtata ttatattgttgc ttccagcaca 2220
 gtttttagaga acaatttttgc taattttatgc ataaaggtaga atatttttgc atataaaattt 2280
 tggctggcgat gggaaatatttgc ttatttttttttgc aaacaactac atccggcata tcattctgc 2340
 ttctcttttgc ttgttacaat gatataact gtttgatgttgc aggataaaat actctgatgc 2400
 caaacggggccctctgcata accatgtca tggcccttc ttttccatgc agctccgtgg 2460
 caacgtgttgc gttattttttgc ttttccatgc ttttggccaa gaattgtat acgacttact 2520
 ataggccgaa ttgttacaat gatataact gtttgatgttgc gggatgtgttgc gacataacgc acggccaaag 2580
 attttttttttgc agctccgtcc acccttcgttgc cggcggatgttgc taacccacccgc 2640
 caaaatgtcat ttgttacaat gatataact gtttgatgttgc aggataaaat actctgatgc 2700
 tccgtcgatc gggatgttgc ttttccatgc ttttggccaa gaattgtat acgacttact 2760
 attttttttttgc ttgttacaat gatataact gtttgatgttgc gacataacgc acggccaaag 2820
 ggtatgttgc agtgcgttgc ccaggagaat gatgttgc ttttggccaa gaattgtat acgacttact 2880
 ccctatgtcc acccttcgttgc cggcggatgttgc taacccacccgc 2940
 ggcctccggg aagggtgttgc ttttggccaa gaattgtat acgacttact 3000
 catggctacg ccagacgttgc aatcttccatgc ttttggccaa gaattgtat acgacttact 3060
 tacggcgttgc gaaatgttgc ttttggccaa gaattgtat acgacttact 3120
 gtaccatcat ggttgcgttgc ttttggccaa gaattgtat acgacttact 3180
 gtttatgtttt gacgttgcgttgc ttttggccaa gaattgtat acgacttact 3240

Fig 34

gcaggtgtta caggccagga acataggact gtgtcagca tccttgactg agggaaagact 3300
 cgccaaactg tccatttcc gcaagaagca attgaaacct tgcgacacag tcatgttctc 3360
 gtaggatct acattgtaca ctgagacag aaagctactg aggagctggc acttaccctc 3420
 cgtattccac ctgaaaggta aacaatcctt tacctgttagg tgcgatacca tcgtatcatg 3480
 tgaagggtac gtatgttaza aaatcaactat gtccccggc ctgtacgta aaacggtagg 3540
 gtacgcccgt acgtatcacg cggaggatt cctagtgtgc aagaccacag acactgtcaa 3600
 aggagaaaaga gtctcatcc ctgtatgcac ctacgtcccc tcaaccatct gtgatcaa 3660
 gactggcata ctagecgacc acgtcacacc ggaggacgca cagaagttgt tagtgggatt 3720
 gaatcagagg atatgttga acgaaagaac actaacacga tgaagaacta 3780
 tctgttcccg atgttgcgc tgcgtttag caagtggcg aggaaataca aggacgac 3840
 ttagatgtgaa aaacctctgg gtgtccgaga gaggttactt acttgtctgt gcttggg 3900
 attaaaaacg aggaagatgc acacatgtt caagaaacca gacacccaga caatagtga 3960
 ggtgccttcgagtttaact cgttctgtcat cccgagctt tggctctacag gcctcgcaat 4020
 cccagtcaga tcacgcatta agatgtttt gcccaagaag accaagcgag agttaatacc 4080
 tgttctcgac gctgtcgtag ccaggatgc tgaacaagag gagaaggaga ggttggagc 4140
 cgagctgact agagaagcct taccacccct cgtccccatc ggcggccgg agacgggagt 4200
 cgtcgacgtc gacgttgaag aacttagata ttcacgttgcgt gcagggttc tggaaaccacc 4260
 tccgcagcgcc ttgaaagtca cccgacagcc gAACGACGTA ctactagaa attacgttagt 4320
 tctgttcccg cagacgttgc tcaagatgttcaagttggc cccgtgcacc ctctacgaga 4380
 gcaggtaaaaataataaacaac taaacgggag ggcggccgg taccaggatcg acggatata 4440
 cggcagggtc ctactaccat gtggatcgcc cattccggc cctgatgttc a2gctttgag 4500
 cgagagcgcc actatgtgt acaacgaaag ggagttgtc aacaggaaac tataccat 4560
 tgccgttcaac ggacgttgc tgaacaccga cgaggagaac tacgagaaag tcaagatgt 4620
 aagaactgac gcegagtacg tgttcgacgt agataaaaaa tgctgcgtca agagagagga 4680
 agcgtcggtt ttgggtttgg tgggagagct aaccaacccc cctgttccatg aattcgccata 4740
 cgaagggtctg aagatcaggc cgtccgcacc atataagact acagtagtag gagtctttgg 4800
 gtttccggggta tcaggcaagt ctgttattat taagggctt tgcacccaaac acgatctgg 4860
 caccagcgcc aagaaggaga actggcagga aatgtttaac gacgtgaaga agcacecgcc 4920
 gaaggggaca agtagggaaa acagtgactc cattctgtca aacgggtgtc gtcgtggcgt 4980
 ggacatccata tatgttgcgtt aggtttcgcc ttgcattcc ggtactctgc tggccctaa 5040
 tgctttgtt aaacctcgga gcaaaagtgg tttatgcggg gaccccaacg aatgcggatt 5100
 cttcaatatg atgcagctta aggttgaactt caaccacaac atctgcactg aagtatgtca 5160
 taaaagtata tccagacgtt gcacgcgtcc agtacacggcc atctgttca ctgtgcacta 5220
 cggaggcaag atgcgcacga ccaacccgtg caacaaaccc ataatcatag acaccacagg 5280
 acagaccaag cccaaaggcag gagacatgtt gtaacatgc ttccgagct gggcaagca 5340
 gtcgcgtt gactaccgtt gacacgtt gacacgacca cccgcaagggtt gtagtgcgtt gacgttgcacc 5400
 gtcgcgtt gtagatgttac tgctgtcgcc cactgaggat gtcgcgtt gtagatgtt gacgttgcacc 5460
 ggcggccgtt ccctggattt aggttcttca aacatttcca caggtaact ttacggccac 5520
 attggaaaga tggcaagaag aacacgacaa aataatgaag gttacttgc tggccctgt 5580
 gctctgtggac gctgtccaga acaaaagcgaa cgtgttgg gcaaaaagcc tgggtccctgt 5640
 Cctggacact gcccgaatca gattgtacgtt gacacgacca agggatgtt gacaccataa ttacagcatt 5700
 taaggaggac agagcttactt ctccatgttgcgtt ggccttgcattt gaaatttgc ccaagacta 5760
 tggagttgac ctggacatgtt gctgttgcgtt gtcgttgcgtt gtttccctgtt attacgagaa 5820
 caaccactgtt gataacacgac ctgttgcgtt gatgttgcgtt ttcattgtcc caacacgttc 5880
 caggctggaa gcttagacata ctttctgttca gggggcgtt gacacgttgc gacggcgtt 5940
 tattgttgcgtt agaaaaatcc aacccgttcc ttttgcgttgcgtt gtttccctgtt attacgagaa 6000
 caggctggcc cacgccttgc tggctgttca gacacgttgcgtt gtttccctgtt attacgagaa 6060
 gtcgttgcgtt gtagatgttac gtttccctgtt gtttccctgtt attacgagaa 6120
 gtcgttgcgtt gtagatgttac gtttccctgtt gtttccctgtt attacgagaa 6180
 gctctgtggac agggatgttac gtttccctgtt gtttccctgtt attacgagaa 6240
 cgcaccaatgtt gtagatgttac gtttccctgtt gtttccctgtt attacgagaa 6300
 tcacacggaa ttcagaatcc accactacca gacgtgttgc gacacgttgcgtt gtttccctgtt attacgagaa 6360
 gatgttgcgtt gtagatgttac gtttccctgtt gtttccctgtt attacgagaa 6420
 cggatgttgcgtt gtagatgttac gtttccctgtt gtttccctgtt attacgagaa 6480
 tgcaagatgtt gtagatgttac gtttccctgtt gtttccctgtt attacgagaa 6540
 caactttgac aacggaaaga gaccccttac gtttccctgtt gtttccctgtt attacgagaa 6600
 cgtgtatgttgcgtt gtagatgttac gtttccctgtt gtttccctgtt attacgagaa 6660

agcagacata gccacgtgca cagaagcgcc tgggttaac gcagctaactg cccgtggaaac 6720
 tgttagggat ggcgtatgca gggccgtggc gaagaaaatgg ccgtcaggct ttaagggagc 6780
 aecaacacca gtggccacaa taaaacagt catgtgcggc tggtaaaaaaactg tcattccacgc 6840
 tgtagcgcct aatttcctcg ccacgactga agcggaaaggg gaccgcgaat tggccgctgt 6900
 ctaccggcca gtggccggcc aagtaaacag actgtcactg agcagectg ccatccccgt 6960
 gctgtccaca ggagtgttca gcggcggaaag agataggctg cagcaatccc tcaaccatct 7020
 attcacagca atggacgcca cggacgctga cgtgaccatc tactgcagag acaaaagttg 7080
 ggagaagaaa atccagaag ccattgacat gaggacggct gtggagttgc tcaatgtatga 7140
 cgtggagctg accacagact tggtagaggt gcacccggac aecagccctgg tgggtcgtaa 7200
 gggctacagt accactgacg ggtcgctgtc ctcgtactt gaaggtaacga aattcaacca 7260
 ggctgtctt gatatggcag agatagtgac gttgtggccc agactgcaag aggcaacga 7320
 acagatatgc ctatacgcc tggcgaaac aatggacaac atcagatcca aatgtccgt 7380
 gaacgattcc gattcatcaa caccctccag gacagtgcctc tgcctgtgcc gctacgcaat 7440
 gacagcagaa cggatcgccc gccttaggtc acaccaagtt aaaagcatgg tggttgtctc 7500
 atctttccc ctcggaaaat accatgtaga tgggtgcag aaggtaaagt gcgagaaggt 7560
 tctccctgttc gacccgacgg tacccctgtt gtttagtccg cggaaagtatg cccatctac 7620
 gacggaccac tcagatcggt cgttacgagg gtttgacttg gactggacca cggactcgctc 7680
 ttccactgccc aecgatatacc tggcgcttcc cagtttgcag tgggtgcaca tggactcgat 7740
 ctacgagcca atggctccca tagtagtgcg ggctgacgtt caccctgaac cccgaggcat 7800
 cggggacccggc gggcagatg tgccacccgtt aaccggcagac catgtggacc tggaaaccc 7860
 gattccctcca ccggcccgaa agagagctgc atacccgttcccccgcggcc cggaggcggacc 7920
 ggtggccggcc cggagaaagc cggacccgtc cccaaaggact gcttttagga acaagctgccc 7980
 tttgacgttcc ggcgacttttgc acgacgacgaa ggtcgatcg tggccctccg ggattacttt 8040
 cggagacttcc gacgacgtcc tggacttagg cccgcccgggt gcatatattt tctccctcgga 8100
 cactggcagc ggacatttttcc aacaaaaatcc cgtttaggcag cacaatctcc agtgcgcaca 8160
 actggatgcg gtccaggagg agaaaatgtt cccggccaaat ttggatactg agagggagaa 8220
 gctgttgctg ctgaaaatgc agatgcaccc atcggaggctt aataagagtc gataccatgc 8280
 tcgcaaaatgtt gagaacatgtt aagccacggt ggtggacagg ctcacatgg gggccagatt 8340
 gtacacggga ggggacgttag gcccacatcc aacatacgcc gttcggtacc cccggccggc 8400
 gtactcccttcc accgttatcg aaagatttcc aagcccccgtt gtagcaatcg cagcgctgca 8460
 cgaatacccttcc cccaaatgtt acccaacagt ggcgtcgatc cagataacag atgaataacga 8520
 cgcatacttcc gacatgttcc acgggtcgga tagttgttcc gacagagcga cattctgccc 8580
 ggcgaagctc cgggtctacc cggaaacatca tgggttccac cagccgactg tacgactg 8640
 cgtccctgtca ccctttccaga acacactaca gaaacgtgttcc gggggccggcc ccaagagaaa 8700
 ctgcaacgtc acgcaaatgc gagaacttacc caccatggac tggcgactgt tcaacgtgg 8760
 gtgtttcaag cgctatgttcc gctccggaga atattggaa gaatgttca aacaacctat 8820
 ccggataacc actgagaaca tcaatccatgttcc gacatgttcc gttaaagggcc cggaaagctgc 8880
 tgecttgcgtt gtaaagaccc acacatgttcc gtcgttccatgttcc ggggttccca tggacagatt 8940
 cacggtcgac atgaaacgg atgtcaaatgtt cactccagggy acggaaacaca cagagggaaag 9000
 accccaaatgtt cggtaatttcc aagcggccggaa gccattggcc acggcttacc tggcgccat 9060
 ccacaggggaa ttagtaagga gactaaatgc tgggttacgc cctaacgtgc acacattttt 9120
 tgatatgtcg gccgaagact ttgacgttccatgttcc gtttttttttccatgttccat 9180
 ggttcttagag acggacatttccatgttcc gtttttttttccatgttccat 9240
 aggttttaatgtt atccctcgaaatgttcc ggttccatgttccat 9300
 agccctttggg gaaatatccatgttcc ggttccatgttccat 9360
 tatgtatgttccatgttcc gtttttttttccatgttccat 9420
 agcaagcgg gttactggcc acggacatccatgttccat 9480
 cggacacatccatgttcc gtttttttttccatgttccat 9540
 ggttccatgttcc ggttccatgttccat 9600
 tggggatccatgttcc gtttttttttccatgttccat 9660
 taagcccttccatgttcc gtttttttttccatgttccat 9720
 gggggatccatgttcc gtttttttttccatgttccat 9780
 ggaggtggccatgttcc gtttttttttccatgttccat 9840
 ggccaccccttcc ggttccatgttccat 9900
 ctacggccgtt cccttccatgttcc gtttttttttccatgttccat 9960
 attataggat ccggccggcc gtttttttttccatgttccat 10020
 gcaaatgttccatgttcc gtttttttttccatgttccat 10080

10/16

atcactgaag aattttatca atcaacatgc agtgcagta gcaaaggcta tcttagtgct 10140
 ctgagaactg gttggtatac cagtgttata actatagaat taagtaatat caagaaaaat 10200
 aagtgtaatg gaacagatgc taaggtaaaa ttgataaaaac aagaattaga taaatataaa 10260
 aatgtctgtaa cagaattgca gttgtcatg caaagcacac cagcagcaaa caatcgagcc 10320
 agaagagaac taccaaggtt tatgaattat acactcaaca atgccaaaaa aaccaatgt 10380
 acattaagca agaaaaggaa aagaagattt ctgggtttt tgtaggtgt tggatctgca 10440
 atcgccagtg gcggtgtgt atcttaaggc ctgcacccat aaggaaatgg gaacaagatc 10500
 aaaatgtctc tactatccac aaacaaggct gtatgtcatg tatcaaattgg agttatgtc 10560
 ttaaccagca aagtgttata cctcaaaaaac tatatagata aacaatttgtt acctattgt 10620
 aacaagcaaa gtcgcagcat atcaaatata gaaaactgtga tagagttcca acaaaaagaa 10680
 aacagactac tagagattac cagggattt agtgttaatg caggtgtaa tacacctgt 10740
 agcacttaca tgtaactaa tagtgaatta ttgtcattaa tcaatgatgat gcctataaca 10800
 aatgatcaga aaaagttat gtccacaat gttcaatag ttagacagca aagttactct 10860
 atcatgtcca taataaaaaga ggaagtctt gcatatgttag tacaattacc actatatgt 10920
 gttatagata caccctttt gaaactacac acatccccctc tatgtacaac caacacaaaa 10980
 gaagggtcca acatctgttt aacaagaat gacagaggat ggtactgtga caatgcagg 11040
 tcagtatctt tcttccacca agctgaaaca tgtaaagggtt aatcaaattcg agtattttgt 11100
 gacacaatga acagtttaac attaccaatg gaaataaaatc tctgcaatgt tgacatattc 11160
 aaccccaaat atgattgtaa aattatgact tcaaaaaacag atgtaaaggc ctccgttatac 11220
 acatctctag gagccatgtgt gtcatgtat qcacaacta aatgtacagc atccaataaa 11280
 aatcgtggaa tcataaaagac atttctaac ggggtgcgatt atgtatcaaa taaaggatg 11340
 gacactgtgt ctgttagtta cacattatata tatgtaaata agcaagaagg taaaagtctc 11400
 tatgtaaaag gtgaaccaat aataaatttc tatgaccctat tagtattccc ctctgtgaa 11460
 tttgtatgcat caatatctca agtcaacacg aagattaaacc agagcctacg atttattcgt 11520
 aaatccgtatg aattattaca taatgttaat gctggtaaat ccaccacaaa tatcatgact 11580
 tgataatgtg gatccagatc cccggtaattt aattgttaat catccctacg caaacgtttt 11640
 acggcccgccg gtggccggcc cgccccggg cccgtccctt gccgtgcag gccactccgg 11700
 tggctccctgt cgtccccggc tccaggcccc agcagatgca gcaactcatc agcgcggtaa 11760
 atgcgcgtgac aatgagacag aacgcatttgc ctctgtctag gcctccaaaa ccaaagaaga 11820
 agaagacaac caaaccaaag ccgaaaacgc agcccaagaa gatcaacgggaaaacgc 11880
 agcaaaagaa gaaagacaag caagccgaca agaagaagaa gaaaccgggaaaagagaaa 11940
 gaatgtgcat gaagattgaa aatgactgtatc tccgtatg cggctagcca cagtaacgt 12000
 gtgtttcccg acatgtccggg caccgcacta tcatgggtgc agaaaatctc ggggtgtctg 12060
 ggggccttcg caatccggc tatctgtgtg ctgggtgtgg tcacttgcat tgggtccgc 12120
 agataatgtt gggtagtca tggcattgtatgcaagaa aattgaaaac agaaaaatgtt 12180
 agggtaagca atggcatata accataactgtataactgtt aacaaagcgc aacaagacct 12240
 ggcgcattgg cccctgtgtc cgcctcacgg aaactccggg caactcatc tgacacatta 12300
 attggcaata attggaaatc tacataagct taattcgacg aataattggaa tttttat 12360
 attttgcaat tggtttttaa tatttccaaa aaaaaaaaaaaaaaaa aaaaaaaaaaaaaaaa 12420
 aaaaaaaaaaaa aaaaaaaaaaaa aaaaaaaaaaaa aaaaaaaaaacta gccccgtccgc atggcatctc 12480
 cacctccctcg cggccgacc tggccatccg aaggaggacg cacgttccact cggatggcta 12540
 agggagagat ccagatctgc tgccttctt agttgcacgc catctgtgtt ttgcccctcc 12600
 cccgtccctt ctttgcaccc ggaagggtgc acccccactg tccttccataaaaatgt 12660
 gaaattgtcat cgcattgtct gaggtaggtt catttttttgggggtgg ggtggggcag 12720
 gacagcaagg gggaggatgg ggaagacaat agcaggatgt ctggggatgc ggtgggtct 12780
 atgggtatccc aggtgtctaa gattgaccc ggttccctt gggccagaaa gaagcaggca 12840
 catcccttc tctgtacac accctgttca cgccttgcgt tcttagttcc agccccactc 12900
 ataggacact catagtctcag gagggtccg ctttcaatcc accccgttaa agtacttgg 12960
 gcggtctctc cttccctcat cagccccacca aacccaaacctt agcctccaag agtggaaaga 13020
 aattaaagca agataggcta ttaagtgcag agggagagaa aatgccttca acatgtgagg 13080
 aagtaatgaa agaaatctca gatttctt cgccttgcgt ctcactgact cgctgcgtc 13140
 ggtcggtcg gtcggcggag cggtatcagc tcaactcaag gggtaatac ggttattccac 13200
 agaattcaggg gataacgcag gaaagaacat gtgagcaaaa ggccagcaaa aggccaggaa 13260
 ccgtaaaaag gccgcgttgc tgggtttt ccataggctc cgccttgc acgagcatca 13320
 caaaaaatcgca cgcctcaatgc agagggtggcg aaacccgaca ggactataaa gataccaggc 13380
 gtttccccctt ggaagctccc tcgtgcgtc ttctgttccg accctgcgcg ttacccggata 13440
 cctgtccgc ttttccctt cggaaagcgt ggcgtttctt catagctcac gctgttaggt 13500

1430

11/16

tctcagttcg gtgttaggtcg ttgcgtccaa gctgggctgt gtgcacgaac ccccggtca 13560
gccccgacgc tgcgccttat ccggtaacta tcgttcttgcg tccaacccgg taagacacga 13620
cttatacgcc ca tggcagcag ccactggtaa caggattac agagcgaggt atgtaggcgg 13680
tgctacagag ttcttgcgtat ggtggcctaa ctacggctac actagaagaa cagtatttgg 13740
tatctgcgtat ctgctgttgc cagttacccc cggaaaaaaa gttggtagct cttgtatccgg 13800
caaacaacc accgctggta gccgggttttttttttgc aagcagcaga ttacgcgcag 13860
aaaaaaaaagga tctcaagaag atcccttgc tttttctacg gggctgcacg ctcagtgaa 13920
cgaaaaactca cgtaaggaa ttttgcgtat gagattataa aaaaggatct tcacccat 13980
ccttttaaat taaaatgaa gttttaaatc aatctaaatg atatatgagt aaacctggtc 14040
tgacagttac caatgtttaa tcgttgcggc acctatctca ggcgcgttgc tatttgcgtt 14100
atccataggat gcgttgcactcg gggggggggg ggcgcgttgc ggcgcgttgc aagaagggt 14160
tgctgactca taccggcct gaatcgcccc atcatccgcg cagaaatgtg gggagccacg 14220
gttgcgttgc gctttttgtt agtggacca gttgggtattt ttgcgttgc 14280
ggaacggctt gcggttgcgg gaagatgcgt gatctgtatcc ttcaactcag caaaagttcg 14340
attttatttcaaa caaaggccgc gttccgtcaa gtcagcgtaa tgctctgcca gtgttacaac 14400
caatttacca atttgttgc gaaaaactca tcgcgcata aatgaaactg caatttattc 14460
atatcaggat tatcaatacc atattttgc aaaaaggccgtt tctgtatgc aggagaaaac 14520
tcacccggcgc agttccatag gatggcaaga tcctgggtatc ggtctgcgt tccgactcgt 14580
ccaaacatcaa tacaacctat taattttttcc tcgtcaaaa taagggttgc aagtggaaaa 14640
tcacccatgag tgacgactga atccgggtgag aatggcaaaa gcttgcgtat ttcttccag 14700
actttttcaaa caggccgcgc attacgcgtcg tcatccatc cactcgccatc aacccaaaccg 14760
ttatccatc tgatggcgc tcgttgcgaga cggaaatcgc gatcgctgtt aaaaggacaa 14820
ttacaaacag gaatcgatg caaaccggcgc aggaacactg ccagcgccatc aacaatattt 14880
tcacccgtatc caggatatttcc ttcaatacc tggatgcgt ttttccggg gatcgactg 14940
gtgagtaacc atgcgtatcagg aggatgcgtt gatggcgtt gatggcgtt aagaggcata 15000
aattccgtca gccaggtag tctgaccatc tcatctgtaa catcatggc aacgcgtatc 15060
ttggccatgtt tcagaacacaa ctctggcgca tcgggcttcc catacaatcg atagattgtc 15120
gcacccgtt gccccgacatt atcgccgagcc catttataacc catataaacc agcatccatg 15180
ttggaaattt atcgccgccc tggatgcgtt gatggcgtt gatggcgtt aatggcgtt 15240
cttgcgttgc tttttatgcg tttttatgcg tttttatgcg tttttatgcg tttttatgcg 15300
tgcgttgcgtt aacatcgatg attttgcgtt gatggcgtt gatggcgtt aatggcgtt 15360
tggatgcgtt atcgccgccc tttttatgcg tttttatgcg tttttatgcg tttttatgcg 15420
aataaaacaaa taggggttcc gccgcacattt ccccgaaaag tggccacatc gatggcgtt 15480
accatttataa tcatgcgtt aacccatc aataggcgta tcacggccatc ctttcgtc 15538

fw 34

12/16

Figure 4. Anti-RSV F titres in sera from mice taken 4 weeks after priming and 2 weeks after boosting




Figure 5 Ribozyme linker for pMP42

5' CTAGGGGTGGCATGGCATCTCCACCTCCCTCGGGTCCGACCTGGGATCCGAAGGAGGACGCAGTCACACTCGGATGGCTAACGGAGA
GCCAGCCGTACCGTAACGGTTGAGGTGAGGCTGGACCCGCTGGTAGGCTTCCCTCCTGCGTAGGCTAACGGATCCCTCTAG

Figure 6 SFV Eco RV-Spe I fragment ligated to ribozyme

	atccggcgttg	cgccttccag	gagaatgatg	tctacgcaca	aataccactg	cgttatggcc	60
5	atgcgcgacg	cagaagaccc	cgaaaggctc	gatagctacg	caaagaaaact	ggcageggcc	120
	tccgggaagg	tgctggatag	agagatcgca	ggaaaaaatca	ccgacctgca	gacegtcatg	180
	gtacgcgg	acgctgaatc	tcctacctt	tgcctgcata	cagaegtcac	gtgtcgtagc	240
	gcagccgaag	tggccgtata	ccaggaegtg	tatgtctgtac	atgcaccaac	atcgctgtac	300
	catcaggcga	tgaaaggtgt	cagaacggcg	tatggattg	ggtttgacac	caccccggtt	360
10	atgtttgacg	cgctagcagg	cgcgtatcca	acctacgcca	caaatactggc	cgacgagcag	420
	gtttacagg	ccaggaacat	aggactgtg	gcgatctct	tgactgggg	aagacteggc	480
	aactgttca	ttctccycaa	gaagcaattt	aaaccttgcg	acacagtcat	gttctcggt	540
	ggatctacat	tgtacactga	gagcagaaag	ctactgagga	gctggcactt	accctccgt	600
	tcccacctga	aaggtaaaca	atcccttacc	tgttaggtgc	ataccatcg	atcatgtgaa	660
	gggtacgtag	ttaagaaaat	cactatgtgc	ccccggctgt	acggtaaaac	ggtagggtag	720
15	gcccgtacgt	atcaeggg	gggatctca	gtgtgcaaga	ccacagacac	tgtcaamgga	780
	gaaagagtct	cattccctgt	atgcacctac	gtccccctca	ccatctgtga	tcaaatgact	840
	ggcataactag	cgccgeacgt	cacacccggag	gagcacakaga	agttgttagt	gggattgaat	900
	cagaggatag	ttgtgaacgg	aagaacacag	cgaacacacta	acacgtatgaa	gaactatctg	960
20	cttccgtatg	tggcgttgc	atttgcga	tggcggaggg	aatacaagge	agacettgtat	1020
	gatggaaaac	ctctgggtgt	ccggagaggg	tactactt	gttctgttt	gttggccatt	1080
	aaaacgagga	agatgcacac	catgtacaa	aaaccagaca	cccaagacaat	agtgaaggtg	1140
	cttcagagt	ttaactcggt	cgtcatcccg	agctatgtt	ctacaggcc	cgcaatccca	1200
	gtcaagatcac	gcattaagat	gctttggcc	aagaagacca	agcyagaggtt	aataactgtt	1260
	ctcgtacgt	cgtcagccag	ggatgtcgaa	caagaggaga	aggagaggtt	ggagggccag	1320
25	ctgacttagag	aagccttacc	accctctgtc	cccategegc	ccggggagag	gggagtcgtc	1380
	gacgtcgacg	ttaagaact	agagtatcac	gcaagggtcag	gggtctgttt	aacacccctgc	1440
	agcgttgta	aagtccaccc	acaggccac	gactactac	taggaaaattt	cgttagtttgc	1500
	tcccccggaga	cctgtctca	gagetc	ttggcccccg	tcacccctct	agcagagcag	1560
	gtggaaaataa	taacacataa	cgggaggggc	ggcggttacc	aggtcgacgg	atatgacggc	1620
30	agggtcttac	taccatgtgg	atcgccatt	ccggccccgt	agtttcaagc	tttgagcgag	1680
	agggccacta	tgggtgtacaa	cgaaaggggag	ttctcaaca	gaaaactata	ccatattgc	1740
	gttcacggac	cgtegtgaa	cacggacag	gagaactacg	agaaagtctag	agctgaagaa	1800
	actgacggcc	agtactgttt	cgacgtatag	aaaaaatgtt	ggctcaagag	agaggaagcg	1860
	tegggttgg	tgttgggtgg	agagcttaacc	aaaaaccctgt	ccctactacaa	cgccctactaa	1920
35	gggtctgaaga	tccaggccgtc	ggcaccat	aagactacag	tagtaggat	tttgggggtt	1980
	cogggatcg	gcaagtctgc	tattataag	agctctgtgc	caaaaacacga	tctgttacc	2040
	agccggcaaga	aggagaactg	ccaggaataa	gttaacgacg	tgaagaagca	ccggggaaag	2100
	gggacaagta	ggggaaaacag	tgactccatc	ctgtctaaacg	ggtgcgtc	tgccgtggac	2160
	atccatatatg	tggacgaggc	tttgcgttgc	catccggta	ctctgttgc	cctaattgt	2220
40	cttggtaaac	ctcgagca	agtgggttta	tgccgagacc	ccaagcaatg	cggttcttc	2280
	aatatgtatgc	agcttaaggt	gaacttcaac	cacaacatct	gcactgaatg	atgtcataaa	2340
	agtatatcc	gaectgttgc	cggtccagtc	acggccatcg	tgtctactgt	gcactacgg	2400
	ggcaagatgc	gcacgaccaa	cccggtcaac	aaaccatata	tcatagacac	cacaggacag	2460
	accaagccca	agccggaggaa	catcggttta	acatgttttc	gaggctggcc	aaagcagctg	2520
45	cagggtact	acgctggaca	cgaaegtatg	acagcagcag	catctcagg	cctccacccgc	2580
	aaagggttat	acgcggtaa	cgagaagggt	aataaaaatc	ccttgtatgc	ccctgtgtcg	2640
	gagcacgt	atgtactgt	gacgcgcact	gaggataggc	ttgtgtggaa	aacgctggcc	2700
	ggcgatccct	ggatttaagg	cctatcaa	atcccacagg	taactttac	ggccacattt	2760
	gaagaatggc	aagaagaaca	cgacaaaata	atgaagggt	ttgaaggacc	ggctgtccct	2820
50	gtggacgcgt	tccagaacaa	agcgaacgt	tgttggcga	aaagcctgtt	gtctgtctg	2880
	gacactgcgg	gaatcagatt	gacagcag	gagtggac	ccataattac	agcatatata	2940
	gaggacagag	cttactctcc	agtggggcc	ttgaatgaaa	tttgcacca	gtactatgg	3000
	gttgcacgtt	acagtggcc	gttttctgc	ccgaagggt	ccctgttata	cgagaacac	3060
	cactggata	acagaccttg	tggaaaggat	tatggattca	atccgc	agctgccagg	3120
	ctgaaagcta	gacatactt	cctggaaagg	cagtggcata	ccggcaagca	ggcagtttac	3180
55	gcagaaagaa	aaatccaaac	gtttctgt	ctgacaaatg	taatttctat	caacccggc	3240
	ctggccgcacg	ccctgggtgg	tgactaca	acgtaaaag	gcagtaggg	tgagttggct	3300
	gtcaataaaag	taaggggt	ccacgttct	ctggtgatgt	agtacaac	ggctttgtct	3360
	cgacgcaggg	tcacttgggt	gtcaccgt	aatgtcaca	gcgcggatag	gtgtacac	3420

fc.66

ctaagtttag gactgccggc tgacgcccgc aggttcgact tggtctttgt gaacattcac 3480
 acggaaattca gaatccacca ctaccagcag tgtgtcgacc acgcccataa gctcagatg 3540
 cttgggggag atgcgttacg actgtctaaa cccggccggca tcttgatgag agcttacgga 3600
 5 taccccgata aaatcagcga agetcgttgc tcctccctaa gcagaaaatg ctcgtctgca 3660
 agagtgttgc gccccgattt tgteaccagg aatacagaatg tggctctgtc gttctccaac 3720
 tttgacaaacg gaaagagacc ctctacgata caccagatga ataccaagct gagtgcctgt 3780
 tatgcgggaa aagecatgca cacggccggg tggccacat cctacagatg taagagagca 3840
 gacatagccca cgtgcacaga aecggctgtg gttaaecgacg ctaaccccc tggactgtt 3900
 ggggatggcg tatgcagggc cggtggcgaag aataggccgt cagcccttas gggagcagca 3960
 10 acaccagggtt gcacaattaa aacagtcatg tgcggctcgat accccgtcat ccacgctgtt 4020
 gcccctaatt tctctccac gactgaagcg gaaggggacc gegaattggc cgctgtctac 4080
 cgggcagtgg cgegegaatg aaacagactg tcactgagca gctgtccat cccgtgtgt 4140
 tccacaggag tggctcaggg cgaaagagat aggctgcagc aatccctcaa ccatctattc 4200
 acaccaatgg acgcacccggc cgctgacgtg accatctact gcaagagacaa aagtggag 4260
 15 aaaaaatccc aggaagccat tgacatgagg acggctgtgg agttgtctaa tgatgacgtg 4320
 gagetgacca cagacttggt gagatgcac cggacacaga gctgtgggg tggtaagggc 4380
 tacatgacca ctgacgggtc gctgtactcg tactttggaa gtacaaatc caaccaggct 4440
 gctattgtata tggcagagat aotgacgtt gggccctggac tggcaagggc aaacaacag 4500
 atatgcctat acgegttggc cgaacaaatg gacaaatca gatccaaatg tccggtaac 4560
 20 gatccyact catcaacacc tcccaggaca gtgcctgtcc tggcggctca cgcaatgaca 4620
 gcagaacggc tggccctgc tagtgcacac caagttaaaa gcatgggtt ttgtctatc 4680
 tttccctcc cgaatatacc tggatgtggg gtgcagaagg taaatgtcga gaaggtttctc 4740
 ctgttcgacc cgacgttacc ttcaatgtttt agtccggggg agtgcgcgc atctacgacg 4800
 gaccacttag atcggttgtt acgggggtt gacttggact ggaccacgca ctgttcc 4860
 25 actggcaggc atccatgtc gctacccatgt ttgcgttgtt gtgcacatc ctegttcc 4920
 gagccaatgg ctcccatagt agtgcggct gacytacacc ctgaaacccg aggcatcg 4980
 gacctgggg cagatgtcga ccctgaaccc gcaacccatg tggacccatc gaacccgatt 5040
 ctccacccgc gcccgaagag agetgcatac cttgcctccc gegeggggg ggcacccgtg 5100
 cggcgeccga gaaagccgac gctgeccca aggactgcgt ttaggaacaa gctgcctttg 5160
 30 acgttcggcg actttgacga gcacgaggc gatgcgttgc cctccggat tacttggg 5220
 gatccgtcgc acgttcgtcg acttagggcc gccgggtgcat atattttctc ctggacact 5280
 ggcageggc atttacaaca aaaatccgtt aggccacca atctccatg cgcacaaatg 5340
 gatgcgttcc aggaggagaa aatgtaccgg ccmaaatgg atactgagag ggagaagctg 5400
 ttgtgtctga aatgcagat gacccatcg gaggctaata agtgcata ccaatctcg 5460
 35 aaatgggaga acatgaaagc cacgggtgt gacaggctca catgggggc cagattgtac 5520
 acgggagccg acgttagggc cataccaaca tacgggttc ggtacccccc cccctgtac 5580
 tcccctaccc tgatgaaag atttcaacg cccgtatgtg caatgcacg gtgcacacgaa 5640
 tacctatcca gaaatatacc aacagtggcg tggattaccaga taacagatga atacgacgca 5700
 tacttggaca tggttgacgg gtccgtatgt tggcttggaca gagcgacatt ctggccggcg 5760
 40 aagctccgt gctacccgaa acatcatcg taccacccgc cgactgtacg cagtgcgtc 5820
 cggtcaccc ttcagaacac actacagaacatg tggctagccg cggccacca gagaaaactgc 5880
 aacgttcacgc aatgcgaga actacccacc atggactcg cagtgttca cgtggagtgc 5940
 ttcaaggcgt atgcctgtc cgagaaatat tggaaagaat atgttaaca accttatcccg 6000
 ataaccactg agaacatcac tacatgttgc accaaattga aaggccccaa agctgtgtcc 6060
 45 ttgttcgtca agacccacaa ctgggttccg ctgcaggagg ttccatgtt cagattcacg 6120
 gtgcacatga aacgagatgt caaagtcaatc ccggggacga aacacacaga ggaagaccc 6180
 aaatgtccagg taattcaacg agccggacca ttggcggaccg cttacccgtt cggcatccac 6240
 agggaaattag taaggagact aatgtctgtt ttaacgcccata acgtgcacac attgtttgt 6300
 atgttcggccg aagactttga cgcgtatcact gctctcaact tccacccagg agacccgggtt 6360
 50 cttagagacgg acattgtcattcattcataa agccggaggc acttccttgc tcttacatgg 6420
 ttaatgtatcc tcaatgttccatgggttgcat cttacccgttccatggcgtatc 6480
 ttggggaaa tatccatgtc tcaatgttccatggcgtatc gtttacatggcgtatc 6540
 atgaaatccgg gcatgtttt gactttgtttt attaactgtt ttttgcacat caccatagca 6600
 aecagggtac tggagccagag acttactgtac tccgcctgtt cggcccttcat cggcgacgac 6660
 55 aacatcggtt acggaggatgt ctccgacaaatg ctgtggccg agagggtgcgc gtcgtgggtc 6720
 aacatggagg tgaatgtatc tgacgtgtc atggggcggaa aaccccccata ttttgggg 6780
 ggattcatacg ttttgcacatcg cgtccacacag acggccctgtc gtgttccaga cccacttaag 6840
 cgcctgttca agttggtaa gcccgtatca gctgaagaca agcaggacga agacaggcga 6900
 cgagactgatc gtgacgaggatgtt gtcggacag gcttggggc cgaactggag 6960

614 6c

gtggcactaa catctaggta tgaggttagag ggctgcaaaa gtatcccat agccatggcc 7020
acettggcga gggacattaa ggctttaag aaattgagag gacctttat acacctctac 7080
ggeggctcta gattgtgcg ttaatacaca gaatttgtat tggatctatcg cgcactatta 7140
taggatccag atccccggta attaattgaa ttacatccc acgcaaacgt ttaacggccg 7200
5 ccgggtggcgc ccgcggcccg cgccccgtcc ttggccgttg caggccactc cgggtggctcc 7260
cgtcgtcccc gactttcagg cccagcagat gcagcaactc atcagcgcgg taaaatgcgt 7320
gacaatgaga cagaacgcaa ttgtctctgc taggectccc aaaccaaaa agaagaagac 7380
aaccaaaacca aagccaaaaa cgccagcccaa gaagatcaac ggaaaaaacgc agcacaaaa 7440
gaagaaaagac aagcaagccg acaagaagaa gaagaaaaccc ggaaaaaagag aaagaatgtg 7500
10 catgaagatt gaaaatgact gtatcttcgt atgcggctag ccacagtaac gtatgtttc 7560
cagacatgtc gggcacccgca ctatcatggg tgcagaaaaat ctccgggttgt ctgggggect 7620
tcycacatcgg cgctatcccg gtgttgggttg tggtcacttg cattgggctc cgcagataag 7680
ttagggttagg caatggcatt gatatacgaa gaaaattgaa aacagaaaaaa gtttagggtaa 7740
15 gcaatggcat ataaccataa ctgtataact tgtaacaaag cgcaacaaga cctgcgcata 7800
tggccccgtg gtccgcctca cgaaaaactcg gggcaactca tattgacaca ttaattggca 7860
ataattggaa gtttacataa gtttatttcg acgaataatt ggattttat tttatttgc 7920
aattggttt taatatttcc aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 7980
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 20 ctgcgggtc ggcatggcat ctccacctcc 8040
tcgcggtccg acctgggcat cggaggagg acgcacgtcc actcgatgg ctaagggaga 8100

INTERNATIONAL SEARCH REPORT

Int'l. Appl. No PCT/CA 98/01064

A. CLASSIFICATION OF SUBJECT MATTER IPC 6 C12N15/86 C12N15/45 C07K14/135 C07K14/115 A61K31/70

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols) IPC 6 C12N C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
--

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 96 40945 A (CONNAUGHT LAB ;LI XIAOMAO (CA); EWASYSHYN MARY E (CA); SAMBHARA SU) 19 December 1996 cited in the application see the whole document, especially page 6, lines 2-9; page 14, lines 15-21; and page 23, lines 18-23 ---	1-36
Y	WO 95 27044 A (BIOPTION AB ;LILJESTROEM PETER (SE); GAROFF HENRIK (SE)) 12 October 1995 cited in the application see the whole document, especially page 8, lines 12-22 ---	1-36
A	WO 96 17072 A (VIAGENE INC) 6 June 1996 see the whole document ---	1-36 -/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

23 April 1999

03/05/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Mandl, B

INTERNATIONAL SEARCH REPORT

Int'l. Appl. No.
PCT/CA 98/01064

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	ZHOU X. ET AL.: "Self-replicating Semliki-Forest virus RNA as recombinant vaccine" VACCINE, vol. 12, no. 16, 1994, pages 1510-1514, XP002089524 cited in the application see the whole document -----	1-36
A	LILJESTROEM P. ET AL.: "A NEW GENERATION OF ANIMAL CELL EXPRESSION VECTORS BASED ON THE SEMLIKI FOREST VIRUS REPLICON" BIO/TECHNOLOGY, vol. 9, December 1991, pages 1356-1361, XP000616021 cited in the application see the whole document	1-36
E,L	WO 99 11808 A (CONNAUGHT LAB ;PARRINGTON MARK (CA)) 11 March 1999 cited in the application see the whole document -----	1-9,20, 23,24, 32,35,36

INTERNATIONAL SEARCH REPORT

International application No.

PCT/CA 98/01064

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 20-30 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA 98/01064

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9640945	A 19-12-1996	AU 695527 B AU 6117696 A CA 2223610 A EP 0832253 A US 5843913 A US 5880104 A		13-08-1998 30-12-1996 19-12-1996 01-04-1998 01-12-1998 09-03-1999
WO 9527044	A 12-10-1995	AU 699384 B AU 2155795 A CA 2184261 A EP 0753053 A FI 963860 A JP 9511143 T		03-12-1998 23-10-1995 12-10-1995 15-01-1997 27-09-1996 11-11-1997
WO 9617072	A 06-06-1996	AU 4594996 A EP 0797679 A US 5814482 A US 5843723 A US 5789245 A		19-06-1996 01-10-1997 29-09-1998 01-12-1998 04-08-1998
WO 9911808	A 11-03-1999	NONE		